CEACAM5 and non-small cell lung carcinoma: When the data for autoantibody against CCT5, CEA, and CYFRA 21-1 were combined into a panel and the samples positive for NSCLC were pooled, the sensitivity was 40% (4/10) for identifying stage I NSCLC, which was significant higher than the sensitivity of any individual protein (P<0.05).